Faeth Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Faeth Therapeutics, Inc. (FTH) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $12.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-04
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $6.60M, a 40.00% decline year-over-year.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $6.00M, a 55.56% decline year-over-year.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $8.60M, a 41.14% decline year-over-year.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $11.59M, a 46.71% decline year-over-year.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2025 was $44.69M, a 33.47% decline from fiscal 2024.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $67.18M, a 12.77% increase from fiscal 2023.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $59.58M, a 33.26% decline from fiscal 2022.
- Faeth Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $89.26M, a 187.94% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $12.60M 10-Q · filed 2026-08-04 | $21.20M derived: sum of 3 quarters · filed 2026-08-04 | $32.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-15 | $14.60M derived: sum of 2 quarters · filed 2026-05-15 | $26.19M derived: sum of 3 quarters · filed 2026-05-15 | $37.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $20.19M derived: sum of 2 quarters · filed 2026-03-30 | $31.19M derived: sum of 3 quarters · filed 2026-08-04 | $44.69M 10-K · filed 2026-03-30 |
| 2025-09-30 | $11.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $22.59M derived: sum of 2 quarters · filed 2026-08-04 | $36.09M 10-Q · filed 2025-11-14 | $50.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $24.50M 10-Q · filed 2026-08-04 | $39.12M derived: sum of 3 quarters · filed 2026-08-04 | $60.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $13.50M 10-Q · filed 2026-05-15 | $28.11M derived: sum of 2 quarters · filed 2026-05-15 | $49.87M derived: sum of 3 quarters · filed 2026-05-15 | $68.61M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $14.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $36.37M derived: sum of 2 quarters · filed 2026-03-30 | $55.12M derived: sum of 3 quarters · filed 2026-03-30 | $67.18M 10-K · filed 2026-03-30 |
| 2024-09-30 | $21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $40.50M derived: sum of 2 quarters · filed 2025-11-14 | $52.57M 10-Q · filed 2025-11-14 | $63.44M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $18.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $30.82M 10-Q · filed 2025-08-05 | $41.69M derived: sum of 3 quarters · filed 2025-08-05 | $58.69M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $12.07M 10-Q · filed 2025-05-06 | $22.94M derived: sum of 2 quarters · filed 2025-05-06 | $39.94M derived: sum of 3 quarters · filed 2025-05-06 | $59.34M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $27.88M derived: sum of 2 quarters · filed 2025-03-28 | $47.27M derived: sum of 3 quarters · filed 2025-03-28 | $59.58M 10-K · filed 2025-03-28 |
| 2023-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $36.40M derived: sum of 2 quarters · filed 2024-11-14 | $48.70M 10-Q · filed 2024-11-14 | $46.59M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $31.70M 10-Q · filed 2024-08-06 | $29.59M derived: sum of 3 quarters · filed 2024-08-06 | $60.09M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $12.30M 10-Q · filed 2024-05-09 | $10.20M derived: sum of 2 quarters · filed 2024-05-09 | $40.70M derived: sum of 3 quarters · filed 2024-05-09 | $93.70M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $28.39M derived: sum of 2 quarters · filed 2024-02-29 | $81.40M derived: sum of 3 quarters · filed 2024-02-29 | $89.26M 10-K · filed 2024-02-29 |
| 2022-09-30 | $30.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $83.50M derived: sum of 2 quarters · filed 2023-11-07 | $91.36M 10-Q · filed 2023-11-07 | $107.36M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $53.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $60.87M 10-Q · filed 2023-08-03 | $76.86M derived: sum of 3 quarters · filed 2023-08-03 | |
| 2022-03-31 | $7.86M 10-Q · filed 2023-05-09 | $23.86M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $31.00M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $15.00M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |